You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

durvalumab

Showing 26 - 50 of 367
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Esophagus Adenocarcinoma Trial in Frankfurt (Durvalumab, FLOT, mFOLFOX-6)

Not yet recruiting
  • Esophagus Adenocarcinoma
  • Durvalumab
  • +3 more
  • Frankfurt, Germany
    Institute of Clinical Cancer Research, University Cancer Center
Jan 26, 2023

Hepatocellular Carcinoma Trial (Durvalumab, Tremelimumab)

Not yet recruiting
  • Hepatocellular Carcinoma
  • (no location specified)
Sep 27, 2022

Small Cell Lung Cancer Trial in Seoul (Durvalumab)

Active, not recruiting
  • Small Cell Lung Cancer
  • Durvalumab
  • Seongnam-si, Gyeonggi-do, Korea, Republic of
  • +1 more
Nov 6, 2022

EGFR-Mutated Non-Small-Cell Lung Carcinoma, Small Cell/Neuroendocrine Trial run by the National Cancer Institute (NCI)

Recruiting
  • EGFR-Mutated Non-Small-Cell Lung Carcinoma
  • Small Cell/Neuroendocrine
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Jan 20, 2023

Hepatocellular Cancer, Hepatocellular Carcinoma, Metastatic Hepatocellular Carcinoma Trial run by the NCI (durvalumab,

Recruiting
  • Hepatocellular Cancer
  • +2 more
  • durvalumab
  • +4 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Jan 20, 2023

Muscle Invasive Bladder Cancer Trial in Boston (Durvalumab, Oleclumab)

Completed
  • Muscle Invasive Bladder Cancer
  • Boston, Massachusetts
  • +1 more
Sep 8, 2022

Unresectable Hepatocellular Carcinoma Trial (Durvalumab, Tremelimumab)

Available
  • Unresectable Hepatocellular Carcinoma
  • (no location specified)
Aug 12, 2022

Lung Cancer, Extensive-stage Small-cell Lung Cancer, Radiotherapy Trial (Durvalumab + carboplatin/cisplatin + etoposide,

Not yet recruiting
  • Lung Cancer
  • +2 more
  • Durvalumab + carboplatin/cisplatin + etoposide
  • +2 more
  • (no location specified)
Aug 3, 2022

Head Neck Cancer Trial in Boston (Oral Decitabine, Durvalumab)

Active, not recruiting
  • Head and Neck Cancer
  • Oral Decitabine
  • Durvalumab
  • Boston, Massachusetts
    Massachusetts General Hospital
Oct 30, 2022

Recurrent Head Neck Cancer, Head Neck Cancer, Head and Neck Tumors Trial in Cincinnati (Durvalumab, Cetuximab)

Active, not recruiting
  • Recurrent Head and Neck Cancer
  • +3 more
  • Cincinnati, Ohio
    UC Health
Oct 3, 2022

Pancreatic Cancer, Hepatocellular Cancer, Biliary Tract Cancer Trial in Edmonton (Durvalumab, Gemcitabine, Nab paclitaxel)

Not yet recruiting
  • Pancreatic Cancer
  • +3 more
  • Durvalumab
  • +5 more
  • Edmonton, Alberta, Canada
    Cross Cancer Institute
Feb 1, 2023

Breast Cancer Trial in Houston (Durvalumab, Trastuzumab, Pertuzumab)

Recruiting
  • Breast Cancer
  • Durvalumab
  • +2 more
  • Houston, Texas
    Houston Methodist Cancer Center
Aug 5, 2022

Oral Cavity Squamous Cell Carcinoma Trial in Leuven (Durvalumab, Durvalumab + Tremelimumab)

Active, not recruiting
  • Oral Cavity Squamous Cell Carcinoma
  • Durvalumab
  • Durvalumab + Tremelimumab
  • Leuven, Belgium
    UZ Leuven
May 30, 2022

Biochemically Recurrent Prostate Carcinoma, Prostate Adenocarcinoma Trial in Seattle (biological, drug, other)

Recruiting
  • Biochemically Recurrent Prostate Carcinoma
  • Prostate Adenocarcinoma
  • Durvalumab
  • +3 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Jan 26, 2023

Invasive Breast Cancer, Inflammatory Breast Cancer Stage III, HER2-positive Breast Cancer Trial in Boston (Trastuzumab

Not yet recruiting
  • Invasive Breast Cancer
  • +4 more
  • Trastuzumab deruxtecan
  • Durvalumab
  • Boston, Massachusetts
  • +1 more
Mar 20, 2023

Intermediate Stage of Hepatocellular Carcinoma, Hepatocellular Carcinoma Trial in Baltimore (Durvalumab, Tremelimumab (Cohort A

Recruiting
  • Intermediate Stage of Hepatocellular Carcinoma
  • Hepatocellular Carcinoma
  • Durvalumab
  • +2 more
  • Baltimore, Maryland
    Sidney Kimmel Comprehensive Cancer Center
Oct 6, 2022

RECTAL CANCER Trial in Faenza (Capecitabine, Radiotherapy, Durvalumab)

Recruiting
  • RECTAL CANCER
  • Faenza, Italy
    Ospedale Degli Infermi Uo Oncologia
Jul 19, 2022

NSCLC, Small Cell Lung Cancer Trial in Worldwide (Durvalumab, Cisplatin, Carboplatin)

Active, not recruiting
  • Non-Small Cell Lung Cancer
  • Small Cell Lung Cancer
  • Durvalumab
  • +3 more
  • Houston, Texas
  • +7 more
Feb 1, 2023

Adenocarcinoma of the Pancreas Trial in Miami (Durvalumab, Radiation Therapy)

Active, not recruiting
  • Adenocarcinoma of the Pancreas
  • Durvalumab
  • Radiation Therapy
  • Miami, Florida
    Miami Cancer Institute at Baptist Health, Inc.
Jul 7, 2022

Multiple Myeloma Trial in New York (Tremelimumab, Durvalumab, Prevnar-13)

Terminated
Has Results
  • Multiple Myeloma
  • New York, New York
  • +1 more
Oct 3, 2022

Small Cell Lung Cancer, Lung Cancer Trial in Switzerland (Durvalumab, carboplatin, etoposide)

Recruiting
  • Small Cell Lung Cancer
  • Lung Cancer
  • Durvalumab
  • +3 more
  • Aarau, Switzerland
  • +13 more
Aug 12, 2022

Advanced or Metastatic NSCLC Trial in Moscow, Saint Petersburg, St. Petersburg (Ceralasertib, Durvalumab)

Recruiting
  • Advanced or Metastatic NSCLC
  • Moscow, Russian Federation
  • +7 more
Jul 4, 2023

Recurrent Gynecological Cancer, Metastatic Cervical Cancer, Metastatic Ovarian Cancer Trial in Boston (Durvalumab, Tremelimumab,

Terminated
  • Recurrent Gynecological Cancer
  • +10 more
  • Durvalumab
  • +2 more
  • Boston, Massachusetts
    Martin King
Oct 4, 2022

Chronic Lymphocytic Leukemia, Richter Syndrome, Small Lymphocytic Lymphoma Trial in Rochester (Acalabrutinib, Durvalumab,

Recruiting
  • Chronic Lymphocytic Leukemia
  • +2 more
  • Rochester, Minnesota
    Mayo Clinic in Rochester
Jan 4, 2023

Gastric Cancer, Microsatellite Instability Trial in Milan (Durvalumab, Tremelimumab)

Recruiting
  • Gastric Cancer
  • Microsatellite Instability
  • Milan, Italy
    Fondazione IRCCS Istituto Nazionale dei Tumori di Milano
Aug 3, 2022